Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.45 |
| ▸ | SGK1 | O00141 | 5/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468759 | 0.92 | NTRK1 (0.44) | GRM4NTRK1NTRK2CHEK1PRKD3 | |
| SCHEMBL2471278 | 0.91 | RIPK2 (0.43) | GRM4NTRK1SGK1CHEK1PRKD3 | |
| SCHEMBL14634192 | 0.90 | NTRK1 (0.42) | GRM4NTRK1SGK1NTRK2RIPK2 | |
| SCHEMBL14634112 | 0.89 | GRM4 (0.52) | GRM4NTRK1SGK1NTRK2RIPK2 | |
| SCHEMBL14633733 | 0.88 | PTGS2 (0.49) | NTRK1NTRK2CHEK1PRKD3CDK8 | |
| SCHEMBL14634034 | 0.86 | EPHB4 (0.49) | NTRK2ROCK1CLK4DYRK1BRIPK2 | |
| SCHEMBL14634292 | 0.85 | RIPK2 (0.44) | NTRK1NTRK2RIPK2MAP2K4ITK | |
| SCHEMBL14634186 | 0.84 | RIPK2 (0.41) | NTRK1SGK1NTRK2CHEK1PRKD3 | |
| SCHEMBL2466308 | 0.84 | GRM4 (0.41) | GRM4NTRK1SGK1NTRK2CHEK1 | |
| SCHEMBL2471505 | 0.84 | RIPK2 (0.42) | NTRK1NTRK2RIPK2MAP2K4ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | GRM4 4019/4885NTRK1 797/4885SGK1 546/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | GRM4 3206/4885NTRK1 628/4885SGK1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.